Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches

Medicine & Life Sciences

• Janus Kinases 100%
• Squamous Cell Carcinoma of Head and Neck 84%
• Transducers 77%
• Janus Kinase Inhibitors 70%
• Lung Neoplasms 60%
• Neck 57%
• Head 55%
• Thorax 52%
• Hematologic Neoplasms 51%
• ErbB Receptors 48%
• Cell Survival 38%
• CSK Tyrosine-Protein Kinase 37%
• Interleukin Receptors 37%
• STAT Transcription Factors 36%
• Drug Stability 35%
• Erythropoietin Receptors 35%
• Cell Proliferation 33%
• Myeloproliferative Disorders 32%
• Immune Evasion 31%
• Squamous Cell Neoplasms 31%
• Cytokine Receptors 30%
• Dimerization 28%
• Nicotinic Receptors 27%
• Head and Neck Neoplasms 25%
• Neoplasms 24%
• Antineoplastic Agents 24%
• Immune System 20%
• Signal Transduction 19%
• Adenosine Triphosphate 19%
• Phosphotransferases 19%
• Transcription Factors 19%
• Ligands 17%
• Lung 13%
• Therapeutics 12%
• Genes 10%